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Abstract
Biophysical and structural characterization of G protein-coupled receptors (GPCRs) has been
limited due to difficulties in expression, purification, and vitro stability of the full-length
receptors. “Divide and conquer” approaches aimed at the NMR characterization of peptides
corresponding to specific regions of the receptor have yielded insights into the structure and
dynamics of GPCR activation and signaling. Though significant progress has been made in the
generation of peptides that are composed of GPCR transmembrane domains, current methods
utilize fusion protein strategies that require chemical cleavage and peptide separation via
chromatographic means. We have developed an expression and purification system based on
fusion to ketosteroid isomerase, thrombin cleavage, and tandem affinity chromatography that
enables the solubilization, cleavage, and characterization in a single detergent system relevant for
biophysical and structural characterization. We have applied this expression and purification
system to the production and characterization of peptides of the adenosine receptor family of
GPCRs in Escherichia coli. Herein, we demonstrate using a model peptide that includes
extracellular loop 3, transmembrane domain 7, and a portion of the carboxy-terminus of the
adenosine A2a receptor that the peptide is sufficiently pure for biophysical characterization, where
it adopts α-helical structure. Furthermore, we demonstrate the utility of this system by optimizing
the construct for thrombin processing and apply the system to peptides with more complex
structures.
Keywords
Ketosteroid isomerase; Peptide; G-protein coupled receptor; Human A2a receptor; Human A2b
receptor; Escherichia coli
Introduction
G protein-coupled receptors (GPCRs)1 are α-helical seven transmembrane domain proteins
that play critical roles in cellular signaling in response to diverse extracellular ligands.
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Approximately 30% of current small molecule and biological drugs target GPCRs [1], where
the effectiveness and specificity of these pharmaceutical therapies could be vastly improved
by structure-based drug design. To date, medium to high resolution crystal structures of
eight GPCRs have been determined, including rhodopsin [2], the β1 and β2 adrenergic
receptors [3–7], the adenosine A2a receptor [8–10], the CXCR4 chemokine receptor [11],
the dopamine D3 receptor [12], the histamine H1 receptor [13], and the M2 muscarinic
receptor [14]. Opportunities for further development of pharmaceuticals that target GPCRs
are considerable, as the sequencing of the human genome has identified upwards of 1000
GPCRs [15]; however, the expression, purification, and in vitro stability of full-length
GPCRs have impeded the biophysical and structural characterization of this class of
membrane proteins.
Recently, “divide and conquer” approaches, which involve the generation and analysis of
peptides corresponding to GPCR transmembrane (TM) domains, have been utilized to
overcome obstacles that prohibit characterization of full-length GPCRs. For example,
structural characterization by NMR is more easily achieved and less constrained in the
membrane mimetic environment than by crystallography. Furthermore, peptides derived
from rhodopsin and characterized by NMR were shown to adopt secondary structures
similar to those observed by X-ray crystallography [16–19]. In addition, studies of GPCR-
derived peptides offer a unique opportunity: specific regions of the receptor, i.e. regions
responsible for ligand binding, receptor activation or cellular signaling, can be characterized
independently. Since these regions are often quite mobile and poorly resolved, this approach
complements high-resolution crystallography. In fact, this piecemeal approach to GPCR
characterization has led to insights into the structure of full-length GPCRs, including
rhodopsin [16–19], Ste2p, the α-factor receptor of Saccharomyces cerevisiae [20–31], the
neurokinin 1 (NK1) receptor [32], the adenosine A2a receptor [33–37], the μ-opioid receptor
[38,39], and the cannabinoid CB2 receptor [40].
Only recently have GPCR peptides that are composed of more than a single TM been
characterized by this approach, where the cost of chemical synthesis of isotopically labeled
peptides (2H, 13C, 15N) and the inherent hydrophobic character of TM peptides have been
the major obstacles. However, characterization of multiple transmembrane domains of the
μ-opioid receptor, the cannabinoid CB2 receptor, and yeast Ste2p have been achieved
through expression in Escherichia coli of fusion proteins containing the desired peptide
[30,38–40]. In fact, large quantities of the isotopically labeled fusion protein/peptide can be
generated relatively inexpensively by expression in media containing 2H, 13C, and 15N as
sole sources for hydrogen, carbon, and nitrogen. After purification and liberation of the
GPCR peptide from the fusion protein, these multi-TM GPCR peptides have shown highly
α-helical secondary structure in trifluoro-ethanol/water and a variety of detergents [30,38–
40] and provide motivation for further investigations into the “divide and conquer”
approach.
In general, expression of GPCR peptides in E. coli is achieved by constructs with multiple
peptides in tandem or by fusion to carrier proteins that protect the peptide from intracellular
degradation [41]. A number of fusion protein expression systems are commercially
available, including those with maltose binding protein, glutathione S-transferase, small
ubiquitin-like modifier, and thioredoxin. These carrier proteins not only promote solubility
and high expression levels but in some cases also provide convenient means for purification
by affinity chromatography. Other carrier proteins, including ketosteroid isomerase [42], the
N-terminal domain of S. nuclease (SFC120) [43], fusion to E. coli TrpE [44], and the anti-
apoptotic Bcl-2 family protein, Bcl-XL [45], promote insoluble expression and readily form
inclusion bodies. Inclusion body expression often results in the highest expression yields
[46,47], provides a simple procedure for recovery through lysis and centrifugation, and even
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permits the production of toxic peptides [48,49]. Due to their inherent hydrophobic
character, GPCR TM peptides are almost exclusively expressed as fusion proteins with
carriers that drive expression to inclusion bodies.
Though required for the generation of peptides in E. coli, removing the carrier protein is not
always a trivial process. The most common methods for liberating peptides from fusion
proteins involve chemical cleavage through CNBr [42] or acid hydrolysis [50] and are
limited to peptides that do not contain methionine or the acid labile Asp-Pro sequence,
respectively, or require their modification by site-directed mutagenesis. Additionally, the
harsh conditions under which chemical cleavage is achieved requires purification of the
cleavage products by HPLC, where hydrophobic peptides are known to result in low yield
[44,51], poor resolution, and low purity [51]. Alternatively, the peptide may be liberated
from the carrier protein through incorporation of a protease-specific cleavage site, including
those for enterokinase [52], factor Xa 11, tobacco etch virus (TEV) protease [53], and
thrombin [54,55], and combined with purification strategies that utilize detergents or
chaotropes.
We have developed a robust system for the high-level expression and purification of GPCR
peptide fragments in E. coli that exploits methods previously developed for solubilizing and
recovering inclusion bodies with the zwitterionic detergent fos-choline 16 [56]. The
engineered expression system utilizes an N-terminal ketosteroid isomerase (KSI) domain,
redundant Strep-Tactin affinity tags, a thrombin cleavage site, and a nickel affinity tag to
enable the expression and rapid purification of receptor peptides for biophysical and
structural characterization.
Results
A peptide representing extracellular loop 3, transmembrane domain 7, and a portion of the
C-terminus of hA2aR was used as a model peptide for developing peptide expression and
purification protocols (Fig. 1). Unlike many other G protein-coupled receptors (GPCRs),
extensive biophysical and structural characterization of the human adenosine A2a receptor
have been accomplished through biophysical characterization of hA2aR TM peptides
[33,35–37] and the full-length receptor [57,58] as well as through X-ray crystallography
[9,10,59]. Completing the biophysical characterization of the hA2aR TM 7 peptide and
comparing the results with the literature would validate the peptide expression and
purification system and motivate its application to other GPCR-derived peptides.
Designing the expression construct
There have been a number of fusion proteins used for the expression and purification of
GPCR-derived peptides, including those that promote solubility or insolubility of the fusion
protein [22–31,38–40]. Due to the high hydrophobic character of GPCR TM peptides,
carrier proteins designed to promote soluble expression of the fusion protein oftentimes fail
in this regard and instead readily form inclusion bodies. For example, initial attempts in our
lab at expressing GPCR TM peptides that utilized thioredoxin, a carrier protein that
promotes soluble expression, showed that the fusion protein readily formed inclusion bodies
in E. coli (data not shown). Therefore, in lieu of choosing a carrier protein that promotes
soluble expression, we pursued fusion proteins that utilize ketosteroid isomerase (KSI),
which promotes insoluble expression in inclusion bodies in E. coli.
The commercially available vector, pET-31b (Merck KGaA, Germany), was used as a
starting point for developing the expression system; this construct encodes for an N-terminal
KSI leader and contains an in-frame His6 tag for facile immobilized metal affinity
chromatography (IMAC) purification. Directing the fusion protein to inclusion bodies
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exploits our previous success with the recovery of the human neurokinin NK1 receptor, a
GPCR, from inclusion bodies in E. coli [56], where protocols for expression, detergent
solubilization, and IMAC purification have already been optimized.
Unlike our previous work, however, fusion proteins carrying GPCR-derived peptides require
additional preparation and purification steps: the GPCR peptide must be liberated from the
fusion protein and then isolated. As previously described, common methods for liberating
the peptide include chemical cleavage through CNBr or acid hydrolysis at susceptible sites.
This approach, however, does not utilize the detergent-solubilized state of the fusion protein
and requires purification by HPLC, which has confounded the recovery of highly
hydrophobic peptides [44,51]. Thus, we sought alternatives to chemical cleavage that would
permit the cleavage and recovery of fusion proteins in a single detergent system. Our
previous work with solubilizing the NK1 receptor [56] and recent evidence from a
systematic screen of 96 detergents identified that the fos-choline series of detergents (FC9–
16) was the most effective at solubilizing human chemokine receptors from E. coli [60].
Therefore, we used fos-choline 16 as the detergent of choice and the previously developed
expression and purification protocols [56] as the basis for developing peptide expression and
purification methods.
Site-specific proteases, which cleave at specific sequences that are designed into the
expression construct through recombinant DNA methods, are an alternative to chemical
cleavage. And, importantly, thrombin was determined to be insensitive to a panel of 94
detergents, including the fos-choline series (FC10–16) [61]. Thus, a thrombin cleavage site
(LVPRGS) was incorporated between the KSI carrier protein and the peptide of interest in
the expression construct. In order to clarify the peptide of interest from undigested fusion
protein, we have incorporated two Strep-tag II sequences into the construct design: one on
the N-terminus of KSI and one immediately upstream of the thrombin cleavage site. Any
undigested fusion protein carrying the Strep-tag II is bound upon exposure to Strep-Tactin
resin, whereas the GPCR peptide passes unimpeded through the column and is collected in
the flow-through fraction. This clarification step ensures the purity of the GPCR peptide for
biophysical and structural characterization.
Initial expression studies using this construct resulted in IMAC purification yields of ~15–
20 mg/L fusion protein per liter of culture, which is common for KSI-driven fusion protein
expression [42]. However, liberation of the hA2aR TM 7 peptide from the fusion protein
limited overall peptide yields and further optimization of this processing step was
investigated to improve yields.
Thrombin processing efficiency
Even in cases where the detergent does not influence protease activity, ineffective
processing of fusion proteins by the protease can limit high peptide yields. Protease
processing yields are commonly in the range of 60–70% [62] but may be improved by
incorporation of glycine rich linkers flanking the cleavage site [63]. A fusion protein of
hA2aR TM 7 that lacked a glycine-rich linker was produced and purified by IMAC; this
peptide was tested for thrombin processing and found to be 65% cleaved after 24 h. at 4 °C
(Fig. 2). In order to improve the cleavage yields, we incorporated glycine rich linkers
G(GSG)8G upstream and downstream of the thrombin cleavage site. We then determined the
effect of different linker lengths on the thrombin processing efficiency of purified fusion
proteins that differed only in the downstream glycine rich linker, including G(GSG)nG
linkers of n = 8,4,2,1,0 (Fig. 2), as thrombin processing would remove the upstream linker.
Achieving high thrombin processing yields with only very short glycine rich linkers ensured
that contributions of the artificial linker to biophysical and structural characterization are
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minimized. We, therefore, pursued expression and purification of Strep-KSI-G(GSG)8G-
Strep-Thrombin-GGSGG-hA2aR TM 7 that when released from the carrier protein would
result in a peptide corresponding to GSLKGGSGGVD-hA2aR259-316-LEHHHHHH.
Purification of hA2aR TM 7
We purified hA2aR TM 7 for biophysical characterization and validated protocols for
expressing and purifying GPCR peptides in E. coli. One liter of E. coli Rosetta(DE3)/pLysS
culture expressing Strep-KSI-G(GSG)8G-Strep-Thrombin-GGSGG-hA2aR TM 7 was grown
and harvested. Inclusion bodies were extracted, solubilized with fos-choline 16, and purified
by immobilized metal affinity chromatography (IMAC) through selective affinity of the
His6-tag for Ni–NTA resin. Samples were taken after each step of the IMAC purification
and analyzed by SDS–PAGE and Coomassie staining (Fig. 3). Following elution, Strep-
KSI-G(GSG)8G-Strep-Thrombin-GGSGG-hA2aR TM 7 appeared as a single band on
Coomassie-stained SDS–PAGE. Western blot analysis using an anti-His6 antibody
confirmed the identification of the ~29 kDa band.
4 mg Strep-KSI-G(GSG)8G-Strep-Thrombin-GGSGG-hA2aR TM 7 was digested in 10 mL
thrombin cleavage buffer supplemented with 5 mM β-ME and 0.0106% fos-choline 16 at 4
°C with 25 U/mL thrombin. Thrombin digestion resulted in 43% cleavage of the fusion
protein in this case. Other 1L scale studies showed that fresh thrombin and detergent
concentration were critical for best yields (data not shown). Thus, we believe the
uncommonly low cleavage yield compared to our earlier success was the result of the
thrombin preparation or ineffective reduction of the detergent concentration for this
particular preparation. Despite the low cleavage yield, the uncut fusion protein and hA2aR
TM 7 -His6 peptide that contained the His6 tag were readily separated from thrombin and
the KSI-containing digestion product by IMAC. His-tagged proteins were eluted in thrombin
cleavage buffer supplemented with 5 mM β-ME and 0.0106% fos-choline 16 and 500 mM
imidazole (Fig. 4A). Fractions enriched in uncut Strep-KSI-G(GSG)8G-Strep-Thrombin-
GGSGG-hA2aR TM 7 -His6 and hA2aR TM 7 -His6 peptide were combined and separated
by differential affinity for Strep-Tactin resin (Fig. 4B). Flow-through fractions were
collected and analyzed by SDS–PAGE and Coomassie staining. Fractions enriched in pure
peptide were combined and concentrated using a centrifugal concentrator. The hA2aR TM 7
peptide was >95% pure as judged by SDS–PAGE and permitted biophysical characterization
by circular dichroism (CD) spectroscopy. A summary of the processing and purification
steps leading to the final peptide yield appears in Table 3.
β-mercaptoethanol (β-ME) was included throughout the purification of hA2aR TM 7 to
reduce disulfide bonds and promote fusion protein and peptide monomer formation, since
the hA2aR TM 7 peptide contains two cysteines known to form a disulfide bond. However,
β-ME has been known to confound secondary structure characterization by CD spectroscopy
due to inherent optical properties, and was therefore removed prior to CD characterization of
the peptide. Eliminating the reducing agent resulted in the formation of reversible peptide
dimers (Fig. 5A). Peptides dimers were reduced by treatment with DTT indicating that
peptide dimerization is the result of intermolecular disulfide bonds.
Secondary structure
The secondary structure of hA2aR TM 7 was investigated using circular dichroism (CD)
spectroscopy. In order to determine the secondary structure of hA2aR TM 7 of both the
monomeric, reduced and dimeric peptide by CD spectroscopy, samples were obtained in
phosphate buffer and fos-choline 16 with or without the reducing agent TCEP (Fig. 5B),
which previously has been shown to fully reduce the disulfide bonds in the full-length
hA2aR at the concentration tested [64]. CD spectra show that hA2aR TM 7 exhibits α-
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helical structure that is signified by two distinct minima at 208 and 222 nm, in either the
presence or absence of TCEP (Fig. 5B). Addition of TCEP did not result in a significant
change to spectra, indicating that the secondary structure of intermolecular disulfide-bonded
hA2aR TM 7 dimers occupy similar secondary structure to their monomeric counterparts.
Using this spectrum, the α-helical content of the hA2aR TM 7 peptide was estimated to be
~17% (Eq. (2), Materials and Methods) for both buffer conditions.
Analysis of expression for TM peptides derived from the adenosine family of GPCRs
In order to determine whether the expression system could be easily applied to more
complex GPCR peptides, GPCR peptides corresponding to hA2aR TM 7, hA2aR TM 6–7,
hA2aR TM 5–7, and hA2aR TM 6 were subcloned into the pET-31b-Strep-KSI-G(GSG)8G-
Strep-Thrombin-G(GSG)8G vector. Each was transformed into the Rosetta(DE3)/pLysS cell
line and grown in 250 mL cultures. For each culture, samples of cellular lysate, including
soluble and insoluble proteins, were analyzed by SDS–PAGE (Fig. 6A). Of the five fusion
proteins containing hA2aR transmembrane peptides, only fusion proteins containing
peptides of hA2aR TM 7 and hA2aR TM 6 were expressed in Rosetta(DE3)/pLysS at levels
sufficient for detection by SDS–PAGE and Coomassie staining (Fig. 6A). Western blot
analysis using an anti-His6 antibody confirmed that bands identified by Coomassie staining
are indeed the fusion proteins, and also shows that fusion proteins corresponding to hA2aR
TM 6–7 and hA2aR TM 5–7 peptides are expressed, albeit at much lower levels (Fig. 6B). In
addition to lower per cell expression levels, expression of fusion proteins corresponding to
hA2aR TM 6–7, hA2aR TM 5–7 and to a moderate extent hA2aR TM 6 peptides exhibited
severe growth inhibition and in some cases modest cell death, as determined by evaluating
doubling times based on changes to optical density post-induction.
Expression of particularly flexible or disordered peptides in E. coli may have ill effects
despite KSI-driven expression to inclusion bodies. For example, structural flexibility of the
peptide may promote soluble expression and inhibit KSI-driven inclusion body formation or
alternatively, elicit cellular responses that ultimately lead to degradation of the fusion
protein. Mutations to hA2aR created by alanine-scanning mutagenesis and selected for
improvements in thermal stability and either agonist or antagonist conformational
homogeneity have previously been identified [65]. Rant 5 (an antagonist-stabilized mutant
of hA2aR) that contains a single mutation within TM 6 (V239A) was used to generate a TM
6–7 peptide, with the hypothesis that we might observe improved fusion protein expression
yields by reducing TM 6 structural flexibility. However, the fusion protein for Rant 5 TM 6–
7 was not observed by SDS–PAGE and only modestly improved expression yields over
wild-type hA2aR TM 6–7 as determined via Western blot analysis (Fig. 6). Therefore, fusion
protein yields of hA2aR TM 6–7 and TM 5–7 may not lead to the yields required for
structural characterization.
The limited expression yields observed here for fusion proteins of hA2aR TM 6–7 may be
GPCR-specific and not a limitation of the expression system as multi-TM [30,38–40,66] and
full-length GPCRs [56,62,66] have been expressed in E. coli with high yields. To determine
whether limitations to expression yields of fusion proteins of hA2aR TM 6–7 were specific
to hA2aR, fusion protein constructs were generated for TM 7 and TM 6–7 peptides of hA1R
and hA2bR. Analysis of expression via SDS–PAGE and Coomassie staining (Fig. 7A) as
well as Western blot assay (Fig. 7B) showed that all fusion proteins for TM 7 peptides tested
exhibited high expression yields; however, only the fusion protein corresponding to hA2bR
TM 6–7 maintained high expression yields. The fusion protein corresponding to hA1R TM
6–7 exhibited severely diminished expression yields and cells expressing this fusion protein
grew poorly post-induction, where the OD600 at harvest was ~0.5. Small-scale studies
suggested thrombin cleavage of these peptides was efficient in the designed module, so long
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as expression was sufficient, indicating expression was the limiting step in the final peptide
yields.
Discussion
We have developed an expression and purification system for the generation of GPCR-
derived peptides of the adenosine family of receptors based on fusion to ketosteroid
isomerase. The developed approach utilizes the solubilization, thrombin cleavage, and
tandem affinity purification of GPCR peptides in a single detergent system and offers an
alternative to current methods for purifying GPCR-derived peptides that are based on
chemical cleavage and HPLC.
In all cases, thrombin processing efficiency of fusion proteins with glycine rich linkers was
improved over fusion proteins without the linker and resulted in efficiencies up to 95% in 24
h. or less on small-scale preparations (Fig. 2). Furthermore, this thrombin-based strategy for
liberating peptides from the KSI carrier appeared to be general, as all adenosine TM
peptides tested were efficiently cleaved by this method (data not shown). Because the
purification strategy avoids the dependence on chemical cleavage for liberating the GPCR
peptide from the fusion protein, GPCR peptides in this system are ensured to represent
domains within the wild-type receptor without the need for modifying the primary sequence,
which adds an additional advantage over currently used peptide production systems.
We have expressed and purified a model peptide of the human adenosine A2a receptor
comprised of extracellular loop 3, transmembrane domain 7, and a portion of the C-terminus
that contains helix 8 at larger scale to validate the expression and purification system. IMAC
purification resulted in a yield of ~17 mg pure fusion protein per liter of culture and enabled
further processing and purification steps prior to characterization of the hA2aR TM 7
peptide. In this case, yields were sufficient for further processing, but may be improved by
sonication of recovered inclusion bodies in the presence of detergent, as batch-to-batch
purification yields varied significantly, from 10 to 50 mg per liter of culture.
Characterization of the model peptide by CD spectroscopy showed that the peptide adopted
α-helical structure in fos-choline 16 micelles consistent with the full-length receptor. Based
on the spectra obtained, the α-helical content of the hA2aR TM 7 peptide was estimated to
be ~17% (Eq. (2), Materials and Methods) for both buffer conditions investigated. This
differs from the expected content of the hA2aR TM 7 peptide based on the hA2aR crystal
structure (49%) [9] and studies of hA2aR TM 7 peptides in SDS micelles (>70%) and TFE
(~70%) [37]. However, SDS and TFE both promote helix formation and TM 7 in the context
of other helices may retain more helical content. Alternatively, these differences may result
from an inability of the hydrophobic potential of the fos-choline detergent alone to stabilize
helical structure. This observation motivates production and biophysical characterization of
peptides with greater complexity, i.e. peptides that contain multiple α-helical TM domains,
where helix-helix interactions have been shown to promote helix stability [67].
The expression system was extended to peptides of A2aR containing multiple
transmembrane domains. Of the five fusion proteins containing hA2aR transmembrane
peptides, expression of multidomain peptides containing either helix 5 or 6 resulted in much
lower expression yield and growth inhibition and sometimes cell death.
It remains unclear as to why the addition of hA2aR TM 6 to the well-expressing peptide
hA2aR TM 7 caused severely decreased expression levels and cell viability, where the final
OD600 was ~0.5; however, the recent crystal structures of hA2aR [9,10,59] and biophysical
characterization of synthesized peptides corresponding to TM peptides of hA2aR [33,35–37]
yield some clues. These studies suggest that hA2aR TM 6, especially the intracellular
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portion of this TM, is inherently flexible. This structural flexibility contributes to GPCR
activation by accommodating structural rearrangements within the GPCR helical core, but
may contribute to instability or affect folding into inclusion bodies in vivo.
In contrast to the observations for A2aR, the fusion protein corresponding to hA2bR TM 6–7
maintained high expression yields. However, hA1R TM 6–7 also exhibited severely
diminished expression yields and cells expressing this fusion protein grew poorly post-
induction. Peptides corresponding to hA1R TM 6–7 and hA2aR TM 6–7 share the conserved
CPXC motif [68] shown to form a disulfide bond in hA2aR [9,10,59], whereas hA2bR TM
6–7 does not. Mutations that eliminate this conserved motif (APXA) did not improve fusion
protein yields for the pET-31b construct of these peptides (data not shown). It remains
unclear why expression yields of KSI fusion proteins corresponding to hA1R and hA2aR
TM 6–7 are severely limited whereas other peptides and full-length GPCRs expressed in this
system are unaffected (data not shown).
These results highlight the importance of exploring multiple fusion protein constructs for
optimal peptide expression yields; yet, the general approach developed here for liberating
and purifying the peptide of interest are applicable in any system.
Materials and methods
Generating the expression system
DNA encoding a Strep-tag II affinity tag (WSHPQFEK), which enables purification by
affinity for Strep-Tactin affinity resin, was introduced on the N-terminus of ketosteroid
isomerase (KSI) by polymerase chain reaction (PCR) of KSI from pET-31b and cloned into
pET-23b after NdeI and BamHI restriction digest to form pET-23b-Strep-KSI-His6 (primers
listed in Table 1). A second Strep-tag II affinity tag and a thrombin cleavage site (LVPRGS)
were incorporated on the C-terminus of Strep-KSI by ligating annealed oligos into KpnI and
AflII digested pET-23b-Strep-KSI-His6 to form pET-23b-Strep-KSI-Strep-Thrombin-His6.
DNA encoding the glycine-rich linker G(GSG)8G was then incorporated between the Strep-
KSI and Strep-Thrombin cleavage site by cloning annealed oligos into BamHI and KpnI
digested pET-23b-Strep-KSI-Strep-Thrombin-His6 to form pET-23b-Strep-KSI-G(GSG)8G-
Strep-Thrombin-His6. DNA encoding Strep-KSI-G(GSG)8G-Strep-Thrombin was shuttled
into pET-31b by NdeI and XhoI digest. A second G(GSG)8G protein linker was
incorporated after the thrombin cleavage site in pET-31b-Strep-KSI-G(GSG)8G-Strep-
Thrombin-His6 by ligating annealed oligos into AflII and SalI restriction sites to form
pET-31b-Strep-KSI-G(GSG)8G-Strep-Thrombin-G(GSG)8G-His6. A summary of the
cloning strategy appears in Table 2. DNA encoding for peptides of the adenosine A2a
receptor, adenosine A1 receptor, and adenosine A2b receptor were then introduced into
pET-31b-Strep-KSI-G(GSG)8G-Strep-Thrombin-G(GSG)8G-His6by SalI and XhoI
restriction digest. Tables 4–6 contain details of the cloning strategy and the peptides
developed.
A model peptide of A2aR (AA 259–316) composed of extracellular loop 3, transmembrane
domain 7, and a portion of the C-terminus that includes the membrane-associated helix 8
(Fig. 1), was devised based on the design of a 73-residue peptide of the S. cerevisiae alpha-
factor pheromone receptor (Ste2p) that previously has been characterized by NMR [22]. In
previous work on synthetic peptides of hA2aR, TM 7 was shown to have high α-helical
content and biophysical characterization of this peptide could serve to validate the
expression and purification protocols developed.
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Optimizing the protein linker for A2aR TM 7
In order to optimize thrombin digestion, constructs of hA2aR TM 7 that differ in protein
linker length were generated by digesting pET-31b-Strep-KSI-G(GSG)8G-Strep-Thrombin-
G(GSG)8G-A2aR TM 7 with AflII and SalI and ligating annealed oligos corresponding to
G(GSG)4G and G(GSG)2G linkers (Fig. 1B). For linkers of GGSGG and GG, annealed
oligos of GGSGG and GG were ligated into pET-31b-Strep-KSI-G(GSG)8G-Strep-
Thrombin-His6 previously digested with AflII and XhoI restriction sites. DNA encoding for
A2aR TM 7 was then introduced into pET-31b-Strep-KSI-G(GSG)8G-Strep-Thrombin-
GGSGG-His6 and pET-31b-Strep-KSI-G(GSG)8G-Strep-Thrombin-GG-His6at SalI and
XhoI restriction sites.
Expression and immobilized metal affinity chromatography (IMAC) purification
Chemically competent Rosetta(DE3)/pLysS (Novagen) were transformed with the pET-31b
vector containing the GPCR transmembrane peptide of interest. Transformants were selected
by growth on Luria–Bertani (LB) plates supplemented with 100 μg/mL ampicillin and 34
μg/mL chloramphenicol. Cells were grown overnight at 37 °C in 50 mL LB liquid media
supplemented with 50 μg/mL ampicillin and 34 μg/mL chloramphenicol. The overnight
culture was used to inoculate 1 L fresh media at an OD600 of ~0.1 and grown at 37 °C.
When the optical density reached ~0.6, isopropyl-β-thiogalactopyranoside (IPTG) was
added to a final concentration of 1 mM to induce expression. Cells were grown for four
hours post-induction and were then harvested by centrifugation for 5 min at 10,000g. The
cell pellet was resuspended in 20 mL lysis buffer (50 mM sodium phosphate, pH 8.0; 10
mM EDTA, 0.1% Triton X-100; 100 μg/mL lysozyme; complete EDTA-free protease
inhibitors (Roche)). The suspension was treated with three freeze/thaw cycles (−80/37 °C).
After the third thaw, the suspension was supplemented with MgCl2 and DNAse
(Deoxyribonuclease I, Sigma, St. Louis MO) to final concentrations of 20 mM and 20 μg/
mL, respectively. Samples were incubated at 25 °C for 20 min and then were centrifuged at
16,000g for 10 min to separate inclusion bodies from soluble proteins. The pellet was treated
with 20 mL binding buffer (50 mM Tris–HCl, pH 8.0; 300 mM NaCl; 10% glycerol; 5 mM
β-mercaptoethanol (β-ME); 20 mM imidazole) supplemented with 1% (w/v) fos-choline 16
for 1 h. at 25 °C to solubilize inclusion bodies. After centrifuging for 10 min at 16,000g, the
supernatant containing solubilized inclusion bodies was collected and the pellet containing
insoluble material was discarded.
Prior to purification, 5 mL of packed Ni–NTA resin (Qiagen) was pre-equilibrated for 1 h. at
25 °C with 20 mL binding buffer containing 0.1% fos-choline 16 and 20 mM imidazole. The
resin was centrifuged 3,220g for 3 min and the equilibration buffer was removed. The resin
was incubated in batch mode with solubilized inclusion bodies at 4 °C and tumbled gently
on an end-over-end mixer overnight. The resin was centrifuged at 3,220g for 3 min and the
supernatant containing unbound protein was removed. The resin was washed with 20 mL
binding buffer containing 0.1% fos-choline 16 and 20 mM imidazole, then with 20 mL
binding buffer containing 0.1% fos-choline 16 and 30 mM imidazole. The resin was then
washed with 10 mL binding buffer containing 0.1% fos-choline 16 and 50 mM imidazole.
Purified fusion proteins were eluted with 5 mL binding buffer containing 0.1% fos-choline
16 and 500 mM imidazole. Samples taken throughout the purification were analyzed by
SDS–PAGE.
Thrombin cleavage
As determined by SDS–PAGE analysis and Coomassie staining, elutions enriched in
purified fusion protein were pooled and dialyzed against thrombin cleavage buffer (20 mM
Tris–HCl, pH 8.0; 150 mM NaCl; 2.5 mM CaCl2) supplemented with 5 mM β-ME and
0.0106% fos-choline 16. The concentration of dialyzed fusion proteins were determined by
Britton et al. Page 9













UV spectroscopy, where the extinction coefficient for the fusion protein at 280 nm (ε280)
was calculated based on the Gill and von Hippel method [69]. Fusion proteins were diluted
to 0.4 mg/mL in thrombin cleavage buffer supplemented with 5 mM β-ME and 0.0106%
fos-choline and digested at 4 °C with 25 U/mL thrombin (Merck KGaA, Germany) on an
end-over-end mixer. Samples corresponding to time = 0, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16 and
24 h after addition of thrombin were removed, quenched with 5x non-reducing sample
buffer (163 mM Tris–HCl, pH 6.8, 0.25 mg/ml Bromophenol blue, 0.5% SDS, 50%
glycerol), and stored at 4 °C until analysis by SDS–PAGE.
Twenty microliters of each sample were loaded on 16% poly-acrylamide gels and
electrophoresed at 25 °C at 150 V for 1.5 h in SDS running buffer (25 mM Tris–HCl, 192
mM Glycine, 1% SDS, pH 8.3). Following electrophoresis, gels were subjected to
Coomassie staining (10% acetic acid, 10% 2-propanol, 0.25 mg/mL Coomassie blue for 4 h
followed by 10% acetic acid, 0.25 mg/mL Coomassie blue for 4 h). Gels were destained
with 10% acetic acid. Gel images were recorded at a resolution of 650 dpi using an Epson
flatbed scanner. In order to determine thrombin processing efficiency, images were analyzed
using ImageJ software, where the percentage of fusion protein remaining at a given time was
determined by the ratio of optical densities of the fusion protein at t = x, where x = 0, 0.25,
0.5, 1, 2, 4, 8, 16, 24 h and t = 0 h.
Purification of hA2aR TM 7
Expression of pET31b-Strep-KSI-G(GSG)8G-Strep-Thrombin-GGSGG-hA2aR TM 7 -His6
in Rosetta(DE3)/pLysS and IMAC purification of Strep-KSI-G(GSG)8G-Strep-Thrombin-
GGSGG-hA2aR TM 7 -His6 was performed as described previously. IMAC-purified fusion
protein was extensively dialyzed against thrombin cleavage buffer supplemented with 5 mM
β-ME and 0.0106% fos-choline 16 and the concentration of the dialyzed fusion protein was
determined by UV spectroscopy. The fusion protein was then diluted to a concentration of
0.4 mg/mL in 10 mLs of thrombin cleavage buffer supplemented with 5 mM β-ME and
0.0106% fos-choline 16 and digested at 4 °C for 24 h with 25 U/mL thrombin on an end-
over-end mixer. Thrombin cleavage products that contained the His6-tag (uncleaved fusion
protein and hA2aR TM 7) were purified by IMAC. The thrombin cleavage products were
permitted to bind 1 mL Ni–NTA that had previously been equilibrated with thrombin
cleavage buffer supplemented with 5 mM β-ME and 0.0106% fos-choline 16 for 2 h. The
resin was centrifuged 3,220g for 3 min and the supernatant containing unbound protein was
removed. The resin was washed with 10 mL thrombin cleavage buffer containing 5 mM β-
ME, 0.0106% fos-choline 16, and 20 mM imidazole, then with 10 mL thrombin cleavage
buffer containing 5 mM β-ME, 0.0106% fos-choline 16, and 30 mM imidazole. The resin
was then washed with 10 mL thrombin cleavage buffer containing 5 mM β-ME, 0.0106%
fos-choline 16, and 50 mM imidazole. IMAC-purified cleavage products were eluted with 1
mL thrombin cleavage buffer containing 5 mM β-ME, 0.0106% fos-choline 16, and 250
mM imidazole. Samples taken through the purification were analyzed by SDS–PAGE and
proteins were visualized with Coomassie staining.
Elutions enriched in hA2aR TM 7 peptide were combined and further purified from
uncleaved fusion protein by differential affinity for Strep-Tactin resin. A 6 mL Kimble
Chase Kontes FlexColumn was packed with 3 mL high-capacity Strep-Tactin resin (IBA-
GmBH, Germany), washed extensively with water, and equilibrated by gravity flow with 40
mL thrombin cleavage buffer containing 5 mM β-ME and 0.0106% fos-choline 16. Three
column volumes from the second IMAC purification that were enriched in hA2aR TM 7
peptide were applied directly to the Strep-Tactin column. Fractions representing the column
flow-through and additional washes were collected in 3 mL fractions. Samples taken
throughout the purification were analyzed by SDS–PAGE and Coomassie staining.
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Those fractions enriched in purified hA2aR TM 7 peptide were pooled and concentrated
using an Amicon centrifugal concentrator with a molecular weight cutoff of 3.5 kDa
resulting in a final yield of ~ 0.55 mg/mL in 600 μL.
Circular dichroism
The secondary structure of GGSGG-hA2aR TM 7 -His6 in fos-choline 16 was characterized
by circular dichroism spectroscopy. The purified peptide was dialyzed against 20 mM
phosphate buffer, pH 7.4 containing 0.1% fos-choline 16 at 4 °C. This sample was then
incubated with either buffer alone or buffer containing 5 mM Tris[2-carboxyethyl]
phosphine (TCEP) for 1 h. at room temperature. The concentration of hA2aR TM 7 analyzed
by circular dichroism was 41.4 μM.
Far-UV CD spectra were obtained using a Jasco-J-810 spectropolarimeter with Peltier
thermal control. All measurements were taken at 25 °C using a 0.1 cm path-length quartz
cuvette. Spectra were collected from 190 to 250 nm using one nm step resolution and four s
integration time. The appropriate reference CD spectra have been subtracted from the
reported CD spectra for GGSGG-hA2aR TM 7. CD spectra are expressed in mean molar
ellipticities [Θ] (deg cm2dmol−1):
(1)
where Θabs is the observed ellipticity (mdeg), l is the optical path-length (cm), c is the
protein concentration (M) and n is the number of residues in the protein. The percentage of
α-helical content was estimated from the observed molar ellipticity at 222 nm ([Θ]222):
(2)
Applying the expression and purification system to other GPCR peptides
In order to confirm that the expression system is a general method for production of GPCR
transmembrane peptides, the fusion protein system was extended to peptides consisting of
single and multiple transmembrane domains of hA2aR and further validated on peptides of
hA1R and A2bR.
Constructs that differed in the GPCR peptide were generated by digesting pET-31b-Strep-
KSI-G(GSG)8G-Strep-Thrombin-G(GSG)8G with SalI and XhoI and ligating similarly
digested PCR products representing transmembrane peptides of hA2aR, hA1R, and A2bR.
Constructs confirmed by DNA sequencing were transformed into Rosetta(DE3)/pLysS and
selected for growth on LB plates supplemented with 100 μg/mL ampicillin and 34 μg/mL
chloramphenicol. Control Rosetta(DE3)/pLysS and Rosetta(DE3)/pLysS containing a
plasmid for GPCR peptide expression were grown overnight in 10 mL LB media containing
either 34 μg/mL chloramphenicol or 50 μg/mL ampicillin and 34 μg/mL chloramphenicol,
respectively, in a 37 °C water shaker. The overnight culture was used to inoculate 250 mL
fresh LB media supplemented with the appropriate antibiotics at an OD600 of ~0.1 and
grown at 37 °C. When the optical density reached 0.6, expression was induced by the
addition of 1 mM IPTG and permitted to grow for 4 h post-induction. Aliquots
corresponding to 100 mL of the culture were harvested by centrifugation for 5 min at
10,000g. Cell pellets were then resuspended in 1 mL solubilization buffer (20 mM Tris–
HCl, pH 8.0 and 1% SDS), sonicated to homogeneity, and centrifuged at 16,000g for 10 min
to remove any remaining insoluble material. Samples were analyzed by SDS–PAGE and
subsequent Western blot analysis.
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Following electrophoresis, proteins were transferred from the gel to a 0.2 μm nitrocellulose
membrane at 50 V and 4 °C for 2 h in transfer buffer (25 mM Tris–HCl, 192 mM glycine,
20% methanol, pH 8.2). Proteins present on the membrane were detected using a primary
antibody of anti-His6 IgG antibody (Covance, Princeton, NJ) at a dilution of 1:1000 in Tris-
buffered saline (20 mM Tris–HCl, 150 mM NaCl, pH 7.6) containing 0.1% Tween 20 and
5% non-fat milk incubated overnight at 4 °C. The secondary antibody used for detection was
Alexa Fluor® 633 goat anti-mouse IgG diluted to 1:5000. Resulting data were imaged with a
Typhoon 9600™ variable mode imager (GE Bioscience, Piscataway, NJ).
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(A) Topology diagram of hA2aR denoting the model peptide hA2aR TM 7. The hA2aR TM
7 peptide is highlighted in gold, and includes residues 259–316. (B) Schematic of the
expression construct highlighting design elements, including redundant Strep-tag II affinity
tags, the ketosteroid isomerase carrier protein, the thrombin cleavage site, the GPCR
peptide, and a His6 affinity tag. The glycine-rich linker downstream of the thrombin
cleavage site has been varied by the number of GSG repeats, where n is 0, 1, 2, 4, or 8.
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Thrombin processing efficiency differs significantly for fusion proteins with different
linkers. SDS–PAGE (16% acrylamide) shows thrombin processing of Strep-KSI-Strep-
Thrombin-hA2aR TM 7 -His6 (A), Strep-KSI-G(GSG)8G-Strep-Thrombin-GG-hA2aR TM 7
-His6 (B), and Strep-KSI-G(GSG)8G-Strep-Thrombin-GGSGG-hA2aR TM 7 -His6 (C).
Quantification of fusion protein cleavage for Strep-KSI-Strep-Thrombin-hA2aR TM 7 -His6
(yellow), Strep-KSI-G(GSG)8G-Strep-Thrombin-GG-hA2aR TM 7 -His6 (grey), and Strep-
KSI-G(GSG)8G-Strep-Thrombin-GGSGG-hA2aR TM 7 -His6 (green) (D) shows that
thrombin processing efficiency is improved with a glycine-rich linker flanking the cleavage
site. Thrombin (T); fusion protein (FP); KSI-containing cleavage product (K); and hA2aR
TM 7 peptide (P) are indicated with arrows. (For interpretation of the references to color in
this figure legend, the reader is referred to the web version of this article.)
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Analysis of Strep-KSI-G(GSG)8G-Strep-Thrombin-GGSGG-hA2aR TM 7-His6 purification
by IMAC. SDS–PAGE (12% acrylamide) shows samples from each step of the purification
corresponding to 1 OD cells. Solubilized protein following extraction of insoluble fraction
and inclusion bodies with Fos-choline 16 (IB); flow through (FT), 20 mM imidazole wash
(W1); 30 mM imidazole wash (W2); 50 mM imidazole wash (W3); 500 mM imidazole
elutions (E1, E2, E3). Full-length fusion protein (FP) is indicated with an arrow.
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SDS–PAGE (16% acrylamide) shows the purification of GGSGG-hA2aR TM 7 after
thrombin cleavage by a second IMAC step (A) and Strep-Tactin affinity (B). Dialyzed
fusion protein was digested with thrombin and the cleavage products were separated by
IMAC. Samples of each purification step were analyzed including undigested fusion protein
(primary IMAC), digestion products, flow through, 20 mM imidazole wash (W1); 30 mM
imidazole wash (W2); 50 mM imidazole wash (W3); 250 mM imidazole elutions (E1, E2,
E3). IMAC elutions consisting of uncleaved fusion protein and hA2aR TM 7 peptide from
the pooled eluate (E1–E3) were separated by affinity to high-capacity Strep-Tactin resin.
Fractions collected from the flow-through and column washes W1 and W2 representing 3
mL thrombin cleavage buffer supplemented with FC16 are enriched in peptide and not
uncleaved fusion protein. Thrombin (T); fusion protein (FP); KSI-containing cleavage
product (K); and hA2aR TM 7 peptide (P) are indicated with arrows.
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Circular dichroism spectroscopy of A2aR TM 7 indicates α-helical secondary structure.
SDS–PAGE (16% acrylamide) shows that purified and dialyzed hA2aR TM 7 peptide forms
dimers through a disulfide bond, where addition of DTT reduces these intermolecular bonds
(A). Purified hA2aR TM 7 was diluted to 41.4 μM in 20mM phosphate buffer, pH 7.4, 0.1%
Fos-choline 16 with (closed circles) and without (open circles) 5 mM TCEP and
characterized by CD (B). Fusion protein (FP); monomeric hA2aR TM 7 peptide (P-M);
putative dimeric hA2aR TM 7 peptide (P-D) are indicated with arrows.
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Expression of hA2aR TM peptides in E. coli is TM-specific. SDS–PAGE (12% acrylamide)
of cellular proteins corresponding to 1 OD cells analyzed by Coomassie staining (A) and
anti-His6 Western blot (B) shows samples obtained from strains expressing Strep-KSI-
G(GSG)8G-Strep-Thrombin-G(GSG)8G fusion protein with peptides corresponding to
hA2aR TM 7, TM 6–7, TM 5–7 and TM 6. A previously identified mutation in hA2aR TM 6
that stabilizes the antagonist-bound form of hA2aR (Rant 5) [65] had little effect on overall
expression of the hA2aR TM 6–7 fusion protein. Arrows indicate the fusion protein.
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Reduced expression yields of hA2aR TM 6–7 are also observed in A1R TM 6–7 but not for
A2bR TM 6–7. SDS–PAGE (12% acrylamide) of cellular proteins corresponding to 1 OD
cells analyzed by Coomassie staining (A) and anti-His6 Western blot (B) shows samples
obtained from strains expressing Strep-KSI-G(GSG)8G-Strep-Thrombin-G(GSG)8G fusion
protein with peptides corresponding to hA1R, hA2aR and hA2bR TM 7 as well as hA1R,
hA2aR and hA2bR TM 6–7 as indicated. All TM 7 peptides analyzed express at a high level,
whereas only hA2bR TM 6–7 express at a high level. Arrows indicate the fusion protein.
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Table 5
Description of peptides explored in this work. Forward primer (FP) and reverse primers (RP) listed in Table 5.
GPCR Peptide AA Molecular weighta Oligonucleotides PCR Template
hA2aR TM 7 259–316 6962.198 FP A2aR 259, RP A2aR 316 pCDNA 3.1 hA2aR
hA2aR TM 6–7 205–316 13152.621 FP A2aR 205, RP A2aR 316 pCDNA 3.1 hA2aR
hA2aR TM 5–7 170–316 17435.893 FP A2aR 170, RP A2aR 316 pCDNA 3.1 hA2aR
hA2aR TM 6 205–265 6922.217 FP A2aR 205, RP A2aR 265 pCDNA 3.1 hA2aR
Rant 5 TM 6–7 205–316 12968.379 FP A2aR 205, RP A2aR 316 pRG/III-hs-MBP-Rant 5 [65]
hA1R TM 7 260–326 7815.028 FP A1R 260, RP A1R 326 pCDNA 3.1 hA1R
hA1R TM 6–7 208–326 13717.173 FP A1R 208, RP A1R 326 pCDNA 3.1 hA1R
hA2bR TM 7 260–332 8087.404 FP A2bR 260, RP A2bR 332 pCDNA 3.1 hA2bR
hA2bR TM 6–7 211–332 13689.100 FP A2bR 211, RP A2bR 332 pCDNA 3.1 hA2bR
a
Molecular weights are based on the theoretical molecular weights calculated from the peptide primary sequence [70] and correspond to the
peptide alone without contributions from the expression cassette.
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Table 6
Primers used for generating peptides of the adenosine family of GPCRs. SalI to (GTCGAC) and XhoI
(GTCGAC) restriction sites used for sub-cloning are underlined. A silent mutation was created in A2bR TM
6–7 to remove an XhoI restriction site, which is marked in bold.
Forward primers
FP A2aR 259 GCAGCGTCGACTGCCCCGACTGCAGC
FP A2aR 205 CAATAAGTCGACCGACGTCAGCTGAAGCAGATG
FP A2aR 170 GTACGGTCGACGAGGATGTGGTCCCCATGAACTAC
FP A1R 260 CAATAAGTCGACTGCCCGTCCTGCCAC
FP A1R 208 CAAGCAGTCGACCGCAAGCAGCTCAACAAGAAG
FP A2bR 260 GTACGGTCGACCAGCCAGCTCAGGGTAAAAATAAG
FP A2bR 211 GTGAGGTCGACAGGCAGCTTCAGCGCACTGAGCTGATGGACCACTCAAGGACCACCCTCCAGCG
Reverse primers
RP A2aR 316 GTGTACTCGAGTGCCTTGAAAGGTTCTTGCTGCCTC
RP A2aR 265 GTGTGCTCGAGGGCGTGGCTGCAGTCG
RP A1R 326 TGATACTCGAGGTCATCAGGGCGCTCTTCTGG
RP A2bR 332 GTGTGCTCGAGTAGTCCGACACCGAGAGCAG
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